HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Failure of etretinate therapy in twins with severe congenital lamellar ichthyosis.

Abstract
We cared for twin females with severe lamellar exfoliation of the newborn (collodion babies) and a family history of death of two brothers at age 3 months. The twins were given a controlled trial of etretinate (Ro 10-9359, Tigason) after not responding to other therapeutic modalities. One of the infants received 1 mg/kg body weight of the drug for 24 hours, while her identical twin sister did not have the medication. Monthly skin biopsies taken from both patients during nine months of therapy did not demonstrate any histologic difference under light microscopy. The clinical course in both infants was basically the same. Etretinate plasma level measurements proved that the drug was absorbed from the gastrointestinal tract. We conclude that in the very severe forms of congenital lamellar ichthyosis, oral retinoids may fail to produce any beneficial effects.
AuthorsY Waisman, A Rachmel, A Metzker, E Wielunsky, M Nitzan, A Rotem, R Steinherz
JournalPediatric dermatology (Pediatr Dermatol) Vol. 6 Issue 3 Pg. 226-8 (Sep 1989) ISSN: 0736-8046 [Print] United States
PMID2798261 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Etretinate
Topics
  • Administration, Oral
  • Diseases in Twins
  • Drug Evaluation
  • Etretinate (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Ichthyosis (drug therapy, genetics)
  • Infant, Newborn
  • Twins, Monozygotic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: